RT Journal Article
T1 Liver growth factor treatment restores cell-extracellular matrix balance in resistance arteries and improves left ventricular hypertrophy in SHR
A1 Conde, M Victoria
A1 González, M Carmen
A1 Quintana Villamandos, María Begoña
A1 Abderrahim, Fátima
A1 Briones, Ana M
A1 Condezo Hoyos, Luis
A1 Regadera, Javier
A1 Susín, Cristina
A1 Gómez de Diego, Jose Juan
A1 Delgado Baeza, Emilio
A1 Díaz Gil, Juan J
A1 Arribas, Silvia M
AB Liver growth factor (LGF) is an endogenous albumin-bilirubin complex with antihypertensive effects in spontaneously hypertensive rats (SHR). We assessed the actions of LGF treatment on SHR mesenteric resistance and intramyocardial arteries (MRA and IMA, respectively), heart, and vascular smooth muscle cells (VSMC). SHR and Wistar-Kyoto (WKY) rats treated with vehicle or LGF (4.5 μg LGF/rat, 4 ip injections over 12 days) were used. Intra-arterial blood pressure was measured in anesthetized rats. The heart was weighted and paraffin-embedded. Proliferation, ploidy, and fibronectin deposition were studied in carotid artery-derived VSMC by immunocytochemistry. In MRA, we assessed: 1) geometry and mechanics by pressure myography; 2) function by wire myography; 3) collagen by sirius red staining and polarized light microscopy, and 4) elastin, cell density, nitric oxide (NO), and superoxide anion by confocal microscopy. Heart sections were used to assess cell density and collagen content in IMA. Left ventricular hypertrophy (LVH) regression was assessed by echocardiography. LGF reduced blood pressure only in SHR. LGF in vitro or as treatment normalized the alterations in proliferation and fibronectin in SHR-derived VSMC with no effect on WKY cells. In MRA, LGF treatment normalized collagen, elastin, and VSMC content and passive mechanical properties. In addition, it improved NO availability through reduction of superoxide anion. In IMA, LGF treatment normalized perivascular collagen and VSMC density, improving the wall-to-lumen ratio. Paired experiments demonstrated a partial regression of SHR LVH by LGF treatment. The effective cardiovascular antifibrotic and regenerative actions of LGF support its potential in the treatment of hypertension and its complications.
PB American Physiological Society
YR 2011
FD 2011-09-07
LK https://hdl.handle.net/20.500.14352/99724
UL https://hdl.handle.net/20.500.14352/99724
LA eng
NO Conde MV, Gonzalez MC, Quintana-Villamandos B, Abderrahim F, Briones AM, Condezo-Hoyos L, Regadera J, Susin C, Gomez de Diego JJ, Delgado-Baeza E, Diaz-Gil JJ, Arribas SM. Liver growth factor treatment restores cell-extracellular matrix balance in resistance arteries and improves left ventricular hypertrophy in SHR. Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H1153-65. doi: 10.1152/ajpheart.00886.2010. Epub 2011 Jun 3. PMID: 21642499.
NO Ministerio de Educacion y Ciencia
NO Comunidad Autonoma de Madrid-UAM
NO Universidad Autonoma de Madrid
NO Comunidad Autónoma de Madrid
NO Ministerio de Ciencia, Innovación y Universidades
NO Fondo de Investigaciones Sanitarias
DS Docta Complutense
RD 7 jun 2026